Treatment of colorectal cancer in older patients: International Society of Geriatric Oncology (SIOG) consensus recommendations 2013

Annals of Oncology

Volumn 26, Issue 3, 2015, Pages 463-476

  Papamichael, Demetris ^a   Audisio, R A ^b   Glimelius, B ^c   de Gramont, A ^d   Glynne Jones, R ^e   Haller, D ^f   Kohne C H ^g   Rostoft, S ^h   Lemmens, V ^i,j   Mitry, E ^k,l   Rutten, H ^m,n   Sargent, D ^o   Sastre, J ^p   Seymour, M ^q   Starling, N ^r   van Cutsem, E ^s   Aapro, M ^t  

^a Bank of Cyprus Group Oncology Centre   (Cyprus)

^b St Helens Teaching Hospital   (United Kingdom)

^c UPPSALA UNIVERSITY   (Sweden)

^d HÔPITAL SAINT ANTOINE   (France)

^e MOUNT VERNON HOSPITAL   (United Kingdom)

^f UNIVERSITY OF PENNSYLVANIA   (United States)

^g KLINIKUM OLDENBURG   (Germany)

^h OSLO UNIVERSITY HOSPITAL   (Norway)

ⁱ ERASMUS MEDICAL CENTER   (Netherlands)

^j Eindhoven Cancer Registry   (Netherlands)

^k INSTITUT CURIE   (France)

^l LABORATOIRE DES SCIENCES DU CLIMAT ET DE L ENVIRONNEMENT   (France)

^m CATHARINA HOSPITAL   (Netherlands)

ⁿ MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^o MAYO CLINIC   (United States)

^p HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^q UNIVERSITY OF LEEDS   (United Kingdom)

^r ROYAL MARSDEN HOSPITAL   (United Kingdom)

^s Katholieke Universiteit   (Belgium)

^t CLINIQUE DE GENOLIER   (Switzerland)

more..

Author keywords

Colorectal cancer; Geriatric assessment; Guidelines; International society of geriatric oncology; Older; SIOG

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CETUXIMAB; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; MITOMYCIN; OXALIPLATIN; PANITUMUMAB;

AGED; BRACHYTHERAPY; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER STAGING; CANCER SURGERY; COLON CANCER; COLORECTAL CANCER; DRUG EFFICACY; DRUG TOLERABILITY; EXTERNAL BEAM RADIOTHERAPY; FRANCE; GERIATRIC ASSESSMENT; HUMAN; METASTASIS; METASTATIC COLORECTAL CANCER; OVERALL SURVIVAL; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECTUM CANCER; REVIEW; THROMBOEMBOLISM; ADJUVANT CHEMOTHERAPY; COLORECTAL NEOPLASMS; CONSENSUS; EUROPE; GERIATRICS; INTERNATIONAL COOPERATION; MEDICAL SOCIETY; PALLIATIVE THERAPY; PROCEDURES; STANDARDS; TREATMENT OUTCOME; VERY ELDERLY;

AGED; AGED, 80 AND OVER; CHEMOTHERAPY, ADJUVANT; COLORECTAL NEOPLASMS; CONSENSUS; EUROPE; GERIATRIC ASSESSMENT; GERIATRICS; HUMANS; INTERNATIONALITY; PALLIATIVE CARE; SOCIETIES, MEDICAL; TREATMENT OUTCOME;

EID: 84931263561     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdu253     Document Type: Review

References (146)

1. Ferlay J, Shin HR, Bray F et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010; 127: 2893-2917.
2. http://seer.cancer.gov/statfacts/html/ld/colorect.html (5 August 2014, date last accessed).
3. Center MM, Jemal A, Ward E. International trends in colorectal cancer incidence rates. Cancer Epidemiol Biomarkers Prev 2009; 18: 1688-1694.
4. http://www.cancerresearchuk.org/cancer-info/cancerstats/types/bowel/incidence/#Trends (5 August 2014, date last accessed).
5. http://www.ncin.org.uk/cancer_information_tools/ukcis (5 August 2014, date last accessed).
6. Aarts MJ, Lemmens VE, Louwman MW et al. Socioeconomic status and changing inequalities in colorectal cancer? A review of the associations with risk, treatment and outcome. Eur J Cancer 2010; 46: 2681-2695.
7. van Leersum NJ, Janssen-Heijnen ML, Wouters MW et al. Increasing prevalence of comorbidity in patients with colorectal cancer in the South of the Netherlands 1995-2010. Int J Cancer 2013; 132: 2157-2163.
8. Andre T, Boni C, Mounedji-Boudiaf L et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 2004; 350: 2343-2351.
9. Andre T, Tournigand C, Achille E et al. [Adjuvant treatment of colon cancer MOSAIC study's main results]. Bull Cancer 2006; 93(Suppl 1): S5-S9.
10. Schmoll HJ, Van Cutsem E, Stein A et al. ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making. Ann Oncol 2012; 23: 2479-2516.
11. van Gestel YR, Lemmens VE, de Hingh IH et al. Influence of comorbidity and age on 1-, 2-, and 3-month postoperative mortality rates in gastrointestinal cancer patients. Ann Surg Oncol 2013; 20: 371-380.
12. Papamichael D, Audisio R, Horiot JC et al. Treatment of the elderly colorectal cancer patient: SIOG expert recommendations. Ann Oncol 2009; 20: 5-16.
13. Fried LP, Tangen CM, Walston J et al. Frailty in older adults: evidence for a phenotype. J Gerontol A Biol Sci Med Sci 2001; 56: M146-M156.
14. Odden MC, Peralta CA, Haan MN, Covinsky KE. Rethinking the association of high blood pressure with mortality in elderly adults: the impact of frailty. Arch Intern Med 2012; 172: 1162-1168.
15. Robinson TN, Eiseman B, Wallace JI et al. Redefining geriatric preoperative assessment using frailty, disability and co-morbidity. Ann Surg 2009; 250: 449-455.
16. Rockwood K, Mitnitski A. Frailty in relation to the accumulation of deficits. J Gerontol A Biol Sci Med Sci 2007; 62: 722-727.
17. Puts MT, Hardt J, Monette J et al. Use of geriatric assessment for older adults in the oncology setting: a systematic review. J Natl Cancer Inst 2012; 104: 1133-1163.
18. Aparicio T, Girard L, Bouarioua N et al. A mini geriatric assessment helps treatment decision in elderly patients with digestive cancer. A pilot study. Crit Rev Oncol Hematol 2011; 77: 63-69.
19. Barthelemy P, Heitz D, Mathelin C et al. Adjuvant chemotherapy in elderly patients with early breast cancer. Impact of age and comprehensive geriatric assessment on tumor board proposals. Crit Rev Oncol Hematol 2011; 79: 196-204.
20. Chaibi P, Magne N, Breton S et al. Influence of geriatric consultation with comprehensive geriatric assessment on final therapeutic decision in elderly cancer patients. Crit Rev Oncol Hematol 2011; 79: 302-307.
21. Girre V, Falcou MC, Gisselbrecht M et al. Does a geriatric oncology consultation modify the cancer treatment plan for elderly patients? J Gerontol A Biol Sci Med Sci 2008; 63: 724-730.
22. Hamaker ME, Jonker JM, de Rooij SE et al. Frailty screening methods for predicting outcome of a comprehensive geriatric assessment in elderly patients with cancer: a systematic review. Lancet Oncol 2012; 13: e437-e444.
23. Hamaker ME, Vos AG, Smorenburg CH et al. The value of geriatric assessments in predicting treatment tolerance and all-cause mortality in older patients with cancer. Oncologist 2012; 17: 1439-1449.
24. Tan KY, Kawamura YJ, Tokomitsu A, Tang T. Assessment for frailty is useful for predicting morbidity in elderly patients undergoing colorectal cancer resection whose comorbidities are already optimized. Am J Surg 2012; 204: 139-143.
25. Kristjansson SR, Jordhøy MS, Nesbakken A et al. Which elements of a comprehensive geriatric assessment (CGA) predict post-operative complications and early mortality after colorectal cancer surgery? J Geriatr Oncol 2010; 1: 57-65.
26. Kristjansson SR, Nesbakken A, Jordhoy MS et al. Comprehensive geriatric assessment can predict complications in elderly patients after elective surgery for colorectal cancer: a prospective observational cohort study. Crit Rev Oncol Hematol 2010; 76: 208-217.
27. Hurria A, Togawa K, Mohile SG et al. Predicting chemotherapy toxicity in older adults with cancer: a prospective multicenter study. J Clin Oncol 2011; 29: 3457-3465.
28. Deprez S, Vandenbulcke M, Peeters R et al. Longitudinal assessment of chemotherapy-induced alterations in brain activation during multitasking and its relationship to cognitive complaints. J Clin Oncol 2014; 25.
29. Nedrebo BS, Soreide K, Eriksen MT et al. Survival effect of implementing national treatment strategies for curatively resected colonic and rectal cancer. Br J Surg 2011; 98: 716-723.
30. Mitry E, Bouvier AM, Esteve J, Faivre J. Improvement in colorectal cancer survival: a population-based study. Eur J Cancer 2005; 41: 2297-2303.
31. Guyot F, Faivre J, Manfredi S et al. Time trends in the treatment and survival of recurrences from colorectal cancer. Ann Oncol 2005; 16: 756-761.
32. Bouvier AM, Launoy G, Lepage C, Faivre J. Trends in the management and survival of digestive tract cancers among patients aged over 80 years. Aliment Pharmacol Ther 2005; 22: 233-241.
33. Mitry E, Bouvier AM, Esteve J, Faivre J. Benefit of operative mortality reduction on colorectal cancer survival. Br J Surg 2002; 89: 1557-1562.
34. Kopetz S, Chang GJ, Overman MJ et al. Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy. J Clin Oncol 2009; 27: 3677-3683.
35. Padman S, Padbury R, Beeke C et al. Liver only metastatic disease in patients with metastatic colorectal cancer: impact of surgery and chemotherapy. Acta Oncol 2013; 52: 1699-1706.
36. Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer 2013; 49: 1374-1403.
37. Quaglia A, Tavilla A, Shack L et al. The cancer survival gap between elderly and middle-aged patients in Europe is widening. Eur J Cancer 2009; 45: 1006-1016.
38. van den Broek CB, Dekker JW, Bastiaannet E et al. The survival gap between middle-aged and elderly colon cancer patients. Time trends in treatment and survival. Eur J Surg Oncol 2011; 37: 904-912.
39. Sorbye H, Cvancarova M, Qvortrup C et al. Age-dependent improvement in median and long-term survival in unselected population-based Nordic registries of patients with synchronous metastatic colorectal cancer. Ann Oncol 2013; 24: 2354-2360.
40. Maringe C, Walters S, Rachet B et al. Stage at diagnosis and colorectal cancer survival in six high-income countries: a population-based study of patients diagnosed during 2000-2007. Acta Oncol 2013; 52: 919-932.
41. De Angelis R, Sant M, Coleman MP et al. Cancer survival in Europe 1999-2007 by country and age: results of EUROCARE-5-a population-based study. Lancet Oncol 2014; 15: 23-34.
42. Duron JJ, Duron E, Dugue T et al. Risk factors for mortality in major digestive surgery in the elderly: a multicenter prospective study. Ann Surg 2011; 254: 375-382.
43. Bozzetti F. Surgery in the elderly: the role of nutritional support. Clin Nutr 2001; 20: 103-116.
44. Bozzetti F. Nutritional issues in the care of the elderly patient. Crit Rev Oncol Hematol 2003; 48: 113-121.
45. Vanitallie TB. Frailty in the elderly: contributions of sarcopenia and visceral protein depletion. Metabolism 2003; 52: 22-26.
46. Rutten HJ, den Dulk M, Lemmens VE et al. Controversies of total mesorectal excision for rectal cancer in elderly patients. Lancet Oncol 2008; 9: 494-501.
47. Van Steenbergen LN, Steur M, Lemmens VE et al. Minimal excess mortality for long-term colon cancer survivors in the Netherlands 1989-2008. Eur J Cancer 2013; 49: 585-592.
48. Dekker JW, van den Broek CB, Bastiaannet E et al. Importance of the first postoperative year in the prognosis of elderly colorectal cancer patients. Ann Surg Oncol 2011; 18: 1533-1539.
49. Jung B, Pahlman L, Johansson R, Nilsson E. Rectal cancer treatment and outcome in the elderly: an audit based on the Swedish Rectal Cancer Registry 1995-2004. BMC Cancer 2009; 9: 68.
50. Manceau G, Karoui M, Werner A et al. Comparative outcomes of rectal cancer surgery between elderly and non-elderly patients: a systematic review. Lancet Oncol 2012; 13: e525-e536.
51. Fontani A, Martellucci J, Civitelli S, Tanzini G. Outcome of surgical treatment of colorectal cancer in the elderly. Updates Surg 2011; 63: 233-237.
52. Dhesi J. Improving outcomes in older people undergoing elective surgery. J R Coll Physicians Edinb 2010; 40: 348-353.
53. Hermans E, van Schaik PM, Prins HA et al. Outcome of colonic surgery in elderly patients with colon cancer. J Oncol 2010; 2010: 865908.
54. Kristjansson SR, Farinella E, Gaskell S, Audisio RA. Surgical risk and postoperative complications in older unfit cancer patients. Cancer Treat Rev 2009; 35: 499-502.
55. Pettersson D, Cedermark B, Holm T et al. Interim analysis of the Stockholm III trial of preoperative radiotherapy regimens for rectal cancer. Br J Surg 2010; 97: 580-587.
56. Pettersson D, Glimelius B, Iversen H et al. Impaired postoperative leucocyte counts after preoperative radiotherapy for rectal cancer in the Stockholm III Trial. Br J Surg 2013; 100: 969-975.
57. van Leeuwen BL, Kristjansson SR, Audisio RA. Should specialized oncogeriatric surgeons operate older unfit cancer patients? Eur J Surg Oncol 2010; 36(Suppl 1): S18-S22.
58. Bokkerink GM, de Graaf EJ, Punt CJ et al. The CARTS study: chemoradiation therapy for rectal cancer in the distal rectum followed by organ-sparing transanal endoscopic microsurgery. BMC Surg 2011; 11: 34.
59. Doornebosch PG, Ferenschild FT, de Wilt JH et al. Treatment of recurrence after transanal endoscopic microsurgery (TEM) for T1 rectal cancer. Dis Colon Rectum 2010; 53: 1234-1239.
60. Doornebosch PG, Tollenaar RA, De Graaf EJ. Is the increasing role of transanal endoscopic microsurgery in curation for T1 rectal cancer justified? A systematic review. Acta Oncol 2009; 48: 343-353.
61. Vuong T, Devic S, Podgorsak E. High dose rate endorectal brachytherapy as a neoadjuvant treatment for patients with resectable rectal cancer. Clin Oncol 2007; 19: 701-705.
62. Huisman MG, van Leeuwen BL, Ugolini G et al. 'Timed up & go': a screening tool for predicting 30-day morbidity in onco-geriatric surgical patients? A multicenter cohort study. PLoS ONE 2014; 9: e86863.
63. Ansaloni L, Andersson RE, Bazzoli F et al. Guidelines in the management of obstructing cancer of the left colon: consensus conference of the World Society of Emergency Surgery (WSES) and Peritoneum and Surgery (PnS) Society. World J Emerg Surg 2010; 5: 29.
64. Cennamo V, Luigiano C, Coccolini F et al. Meta-analysis of randomized trials comparing endoscopic stenting and surgical decompression for colorectal cancer obstruction. Int J Colorectal Dis 2013; 28: 855-863.
65. Jiang JK, Lan YT, Lin TC et al. Primary vs. delayed resection for obstructive leftsided colorectal cancer: impact of surgery on patient outcome. Dis Colon Rectum 2008; 51: 306-311.
66. Rondelli F, Reboldi P, Rulli A et al. Loop ileostomy versus loop colostomy for fecal diversion after colorectal or coloanal anastomosis: a meta-analysis. Int J Colorectal Dis 2009; 24: 479-488.
67. Andre T, Boni C, Navarro M et al. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol 2009; 27: 3109-3116.
68. Andre T, Colin P, Louvet C et al. Semimonthly versus monthly regimen of fluorouracil and leucovorin administered for 24 or 36 weeks as adjuvant therapy in stage II and III colon cancer: results of a randomized trial. J Clin Oncol 2003; 21: 2896-2903.
69. Moertel CG, Fleming TR, Macdonald JS et al. Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med 1990; 322: 352-358.
70. O'Connell MJ, Mailliard JA, Kahn MJ et al. Controlled trial of fluorouracil and lowdose leucovorin given for 6 months as postoperative adjuvant therapy for colon cancer. J Clin Oncol 1997; 15: 246-250.
71. Lembersky BC, Wieand HS, Petrelli NJ et al. Oral uracil and tegafur plus leucovorin compared with intravenous fluorouracil and leucovorin in stage II and III carcinoma of the colon: results from National Surgical Adjuvant Breast and Bowel Project Protocol C-06. J Clin Oncol 2006; 24: 2059-2064.
72. Tournigand C, Andre T, Bonnetain F et al. Adjuvant therapy with fluorouracil and oxaliplatin in stage II and elderly patients (between ages 70 and 75 years) with colon cancer: subgroup analyses of the Multicenter International Study of Oxaliplatin, Fluorouracil, and Leucovorin in the Adjuvant Treatment of Colon Cancer trial. J Clin Oncol 2012; 30: 3353-3360.
73. Fugueredo A, Coombes ME, Mukherjee S. Adjuvant therapy for completely resected stage II colon cancer. Cochrane Database Syst Rev 2008; CD005390.
74. Andre T, Iveson T, Labianca R et al. The IDEA (International Duration Evaluation of Adjuvant Chemotherapy) Collaboration: prospective combined analysis of phase III trials investigating duration of adjuvant therapy with the FOLFOX (FOLFOX4 or Modified FOLFOX6) or XELOX (3 versus 6 months) regimen for patients with stage III colon cancer: trial design and current status. Curr Colorectal Cancer Rep 2013; 9: 261-269.
75. Haller DG, Tabernero J, Maroun J et al. Capecitabine plus oxaliplatin compared with fluorouracil and folinic acid as adjuvant therapy for stage III colon cancer. J Clin Oncol 2011; 29: 1465-1471.
76. Kuebler JP, Wieand HS, O'Connell MJ et al. Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07. J Clin Oncol 2007; 25: 2198-2204.
77. Yothers G, O'Connell MJ, Allegra CJ et al. Oxaliplatin as adjuvant therapy for colon cancer: updated results of NSABP C-07 trial, including survival and subset analyses. J Clin Oncol 2011; 29: 3768-3774.
78. Twelves C, Wong A, Nowacki MP et al. Capecitabine as adjuvant treatment for stage III colon cancer. N Eng J Med 2005; 352: 2696-2704.
79. Twelves C, Scheithauer W, McKendrick J et al. Capecitabine versus 5-fluorouracil/folinic acid as adjuvant therapy for stage III colon cancer: final results from the X-ACT trial with analysis by age and preliminary evidence of a pharmacodynamic marker of efficacy. Ann Oncol 2012; 23: 1190-1197.
80. Jackson McCleary NA, Meyerhardt J, Green E et al. Impact of older age on the efficacy of newer adjuvant therapies in >12,500 patients ( pts) with stage II/III colon cancer: findings from the ACCENT Database. J Clin Oncol 2009; 27(15S): Abstract 4010.
81. McCleary NJ, Odejide O, Szymonifka J et al. Safety and effectiveness of oxaliplatin-based chemotherapy regimens in adults 75 years and older with colorectal cancer. Clin Colorectal Cancer 2013; 12: 62-69.
82. McCleary NJ, Meyerhardt JA, Green E et al. Impact of age on the efficacy of newer adjuvant therapies in patients with stage II/III colon cancer: findings from the ACCENT database. J Clin Oncol 2013; 31: 2600-2606.
83. Haller D, O'Connell M, Cartwright TH et al. Impact of age and medical comorbidity (MC) on adjuvant treatment outcomes for stage III colon cancer (CC): a pooled analysis of individual data from four randomized trials. J Clin Oncol 2012; 30(15 suppl): Abstract 3522.
84. Beijers AJ, Mols F, Vreugdenhil G. A systematic review on chronic oxaliplatininduced peripheral neuropathy and the relation with oxaliplatin administration. Support Care Cancer 2014; 22: 1999-2007.
85. Mols F, Beijers T, Lemmens V et al. Chemotherapy-induced neuropathy and its association with quality of life among 2-to 11-year colorectal cancer survivors: results from the population-based PROFILES registry. J Clin Oncol 2013; 31: 2699-2707.
86. Tofthagen C. Surviving chemotherapy for colon cancer and living with the consequences. J Palliat Med 2010; 13: 1389-1391.
87. Abraham A, Habermann EB, Rothenberger DA et al. Adjuvant chemotherapy for stage III colon cancer in the oldest old: results beyond clinical guidelines. Cancer 2013; 119: 395-403.
88. Kahn KL, Adams JL, Weeks JC et al. Adjuvant chemotherapy use and adverse events among older patients with stage III colon cancer. JAMA 2010; 303: 1037-1045.
89. Sanoff HK, Carpenter WR, Sturmer T et al. Effect of adjuvant chemotherapy on survival of patients with stage III colon cancer diagnosed after age 75 years. J Clin Oncol 2012; 30: 2624-2634.
90. Sanoff HK, Goldberg RM. Colorectal cancer treatment in older patients. Gastrointest Cancer Res 2007; 1: 248-253.
91. Schrag D, Cramer LD, Bach PB, Begg CB. Age and adjuvant chemotherapy use after surgery for stage III colon cancer. J Natl Cancer Inst 2001; 93: 850-857.
92. van Erning FN, Bernards N, Creemers GJ et al. Administration of adjuvant oxaliplatin to patients with stage III colon cancer is affected by age and hospital. Acta Oncol 2014; 53: 975-980.
93. van Erning FN, Creemers GJ, De Hingh IH et al. Reduced risk of distant recurrence after adjuvant chemotherapy in patients with stage III colon cancer aged 75 years or older. Ann Oncol 2013; 24: 2839-2844.
94. Sorbye H, Pfeiffer P, Cavalli-Bjorkman N et al. Clinical trial enrollment, patient characteristics, and survival differences in prospectively registered metastatic colorectal cancer patients. Cancer 2009; 115: 4679-4687.
95. Aparicio T, Jouve JL, Teillet L et al. Geriatric factors predict chemotherapy feasibility: ancillary results of FFCD 2001-02 phase III study in first-line chemotherapy for metastatic colorectal cancer in elderly patients. J Clin Oncol 2013; 31: 1464-1470.
96. Cunningham D, Lang I, Marcuello E et al. Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label randomized international phase 3 trial. Lancet Oncol 2013; 14: 1077-1085.
97. Seymour MT, Thompson LC, Wasan HS et al. Chemotherapy options in elderly and frail patients with metastatic colorectal cancer (MRC FOCUS2): an openlabel, randomised factorial trial. Lancet 2011; 377: 1749-1759.
98. Aparicio T, Desrame J, Lecomte T et al. Oxaliplatin-or irinotecan-based chemotherapy for metastatic colorectal cancer in the elderly. Br J Cancer 2003; 89: 1439-1444.
99. Folprecht G, Seymour MT, Saltz L et al. Irinotecan/fluorouracil combination in first-line therapy of older and younger patients with metastatic colorectal cancer: combined analysis of 2,691 patients in randomized controlled trials. J Clin Oncol 2008; 26: 1443-1451.
100. Saltz LB, Cox JV, Blanke C et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 2000; 343: 905-914.
101. Douillard JY. Irinotecan and high-dose fluorouracil/leucovorin for metastatic colorectal cancer. Oncology 2000; 14: 51-55.
102. Kohne CH, van Cutsem E, Wils J et al. Phase III study of weekly high-dose infusional fluorouracil plus folinic acid with or without irinotecan in patients with metastatic colorectal cancer: European Organisation for Research and Treatment of Cancer Gastrointestinal Group Study 40986. J Clin Oncol 2005; 23: 4856-4865.
103. Seymour MT, Maughan TS, Ledermann JA et al. Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial. Lancet 2007; 370: 143-152.
104. Francois E, Berdah JF, Chamorey E et al. Use of the folinic acid/5-fluorouracil/irinotecan (FOLFIRI 1) regimen in elderly patients as a first-line treatment for metastatic colorectal cancer: a phase II study. Cancer Chemother Pharmacol 2008; 62: 931-936.
105. de Gramont A, Figer A, Seymour M et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000; 18: 2938-2947.
106. Rothenberg ML, Oza AM, Bigelow RH et al. Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trial. J Clin Oncol 2003; 21: 2059-2069.
107. Goldberg RM, Sargent DJ, Morton RF et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2004; 22: 23-30.
108. Mitry E, Venat-Bouvet L, Phelip JM et al. Randomised phase III in elderly patients comparing LV5FU2 with or without irinotecan for first-line treatment of metastatic colorectal cancer (FFCD 2001-02). Ann Oncol 2012; 23(Suppl 9): Abstract 529PD.
109. Asmis TR, Powell E, Karapetis CS et al. Comorbidity, age and overall survival in cetuximab-treated patients with advanced colorectal cancer (ACRC)-results from NCIC CTG CO.17: a phase III trial of cetuximab versus best supportive care. Ann Oncol 2011; 22: 118-126.
110. Cassidy J, Saltz LB, Giantonio BJ et al. Effect of bevacizumab in older patients with metastatic colorectal cancer: pooled analysis of four randomized studies. J Cancer Res Clin Oncol 2010; 136: 737-743.
111. Folprecht G, Köhne CH, Bokemeyer C et al. Cetuximab and 1st-line chemotherapy in elderly and younger patients with metastatic colorectal cancer (MCRC): a pooled analysis of the CRYSTAL and OPUS studies. Ann Oncol 2010; 21(Suppl 8): Abstract 597P.
112. Kabbinavar FF, Hurwitz HI, Yi J et al. Addition of bevacizumab to fluorouracilbased first-line treatment of metastatic colorectal cancer: pooled analysis of cohorts of older patients from two randomized clinical trials. J Clin Oncol 2009; 27: 199-205.
113. Kozloff M, Bekaii-Saab TS, Bendell JC et al. Effectiveness of first-or second-line bevacizumab (BV) treatment (tx) in elderly patients ( pts) with metastatic colorectal cancer (mCRC) in ARIES, an observational cohort study (OCS). J Clin Oncol 2011; 29(15 suppl): Abstract 3625.
114. Kozloff MF, Berlin J, Flynn PJ et al. Clinical outcomes in elderly patients with metastatic colorectal cancer receiving bevacizumab and chemotherapy: results from the BRiTE observational cohort study. Oncology 2010; 78: 329-339.
115. Price TJ, Zannino D, Wilson K et al. Bevacizumab is equally effective and no more toxic in elderly patients with advanced colorectal cancer: a subgroup analysis from the AGITG MAX trial: an international randomised controlled trial of capecitabine, bevacizumab and mitomycin C. Ann Oncol 2012; 23: 1531-1536.
116. Sastre J, Aranda E, Gravalos C et al. First-line single-agent cetuximab in elderly patients with metastatic colorectal cancer. A phase II clinical and molecular study of the Spanish group for digestive tumor therapy (TTD). Crit Rev Oncol Hematol 2011; 77: 78-84.
117. Sastre J, Gravalos C, Rivera F et al. First-line cetuximab plus capecitabine in elderly patients with advanced colorectal cancer: clinical outcome and subgroup analysis according to KRAS status from a Spanish TTD Group Study. Oncologist 2012; 17: 339-345.
118. Jonker DJ, O'Callaghan CJ, Karapetis CS et al. Cetuximab for the treatment of colorectal cancer. N Engl J Med 2007; 357: 2040-2048.
119. Hurwitz HI, Tebbutt NC, Kabbinavar F et al. Efficacy and safety of bevacizumab in metastatic colorectal cancer: pooled analysis from seven randomized controlled trials. Oncologist 2013; 18: 1004-1012.
120. Tebbutt NC, Wilson K, Gebski VJ et al. Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: results of the Australasian gastrointestinal trials group randomized phase III MAX study. J Clin Oncol 2010; 28: 3191-3198.
121. Figer A, Perez-Staub N, Carola E et al. FOLFOX in patients aged between 76 and 80 years with metastatic colorectal cancer: an exploratory cohort of the OPTIMOX1 study. Cancer 2007; 110: 2666-2671.
122. Koopman M, Simkens LHJ, Ten Tije AJ et al. Maintenance treatment with capecitabine and bevacizumab versus observation after induction treatment with chemotherapy and bevacizumab in metastatic colorectal cancer (mCRC): the phase III CAIRO3 study of the Dutch Colorectal Cancer Group (DCCG). J Clin Oncol 2013; 31(15 suppl): Abstract 3502.
123. Sastre J, Massuti B, Gomez A et al. Phase II study of first-line single-agent panitumumab in frail elderly patients with advanced wild-type KRAS colorectal cancer with poor prognostic factors. Eur Cancer Congress 2013; Abstract 2379.
124. Ayanian JZ, Zaslavsky AM, Fuchs CS et al. Use of adjuvant chemotherapy and radiation therapy for colorectal cancer in a population-based cohort. J Clin Oncol 2003; 21: 1293-1300.
125. Chang GJ, Skibber JM, Feig BW, Rodriguez-Bigas M. Are we undertreating rectal cancer in the elderly? An epidemiologic study. Ann Surg 2007; 246: 215-221.
126. Endreseth BH, Romundstad P, Myrvold HE et al. Rectal cancer treatment of the elderly. Colorectal Dis 2006; 8: 471-479.
127. Faivre-Finn C, Benhamiche AM, Maingon P et al. Changes in the practice of adjuvant radiotherapy in resectable rectal cancer within a French well-defined population. Radiother Oncol 2000; 57: 137-142.
128. Gagliardi G, Pucciarelli S, Asteria CR et al. A nationwide audit of the use of radiotherapy for rectal cancer in Italy. Tech Coloproctol 2010; 14: 229-235.
129. Olsson LI, Granstrom F, Glimelius B. Socioeconomic inequalities in the use of radiotherapy for rectal cancer: a nationwide study. Eur J Cancer 2011; 47: 347-353.
130. Bosset JF, Collette L, Calais G et al. Chemotherapy with preoperative radiotherapy in rectal cancer. N Engl J Med 2006; 355: 1114-1123.
131. Gerard JP, Conroy T, Bonnetain F et al. Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203. J Clin Oncol 2006; 24: 4620-4625.
132. Ngan SY, Burmeister B, Fisher RJ et al. Randomized trial of short-course radiotherapy versus long-course chemoradiation comparing rates of local recurrence in patients with T3 rectal cancer: Trans-Tasman Radiation Oncology Group trial 01.04. J Clin Oncol 2012; 30: 3827-3833.
133. Peeters KC, Marijnen CA, Nagtegaal ID et al. The TME trial after a median followup of 6 years: increased local control but no survival benefit in irradiated patients with resectable rectal carcinoma. Ann Surg 2007; 246: 693-701.
134. Sebag-Montefiore D, Stephens RJ, Steele R et al. Preoperative radiotherapy versus selective postoperative chemoradiotherapy in patients with rectal cancer (MRC CR07 and NCIC-CTG C016): a multicentre, randomised trial. Lancet 2009; 373: 811-820.
135. Martijn H, Vulto JC. Should radiotherapy be avoided or delivered differently in elderly patients with rectal cancer? Eur J Cancer 2007; 43: 2301-2306.
136. Bossema E, Stiggelbout A, Baas-Thijssen M et al. Patients' preferences for low rectal cancer surgery. Eur J Surg Oncol 2008; 34: 42-48.
137. Couture J, Chan R, Bouharaoui F. Patient's preferences for adjuvant postoperative chemoradiation therapy in rectal cancer. Dis Colon Rectum 2005; 48: 2055-2060.
138. Harrison JD, Solomon MJ, Young JM et al. Patient and physician preferences for surgical and adjuvant treatment options for rectal cancer. Arch Surg 2008; 143: 389-394.
139. Kennedy ED, Schmocker S, Victor C et al. Do patients consider preoperative chemoradiation for primary rectal cancer worthwhile? Cancer 2011; 117: 2853-2862.
140. Kornmann M, Henne-Bruns D, Porzsolt F. Neoadjuvant treatment of rectal carcinoma: assessment of health care services by physicians and lay persons. J Clin Oncol 2008; 26: 4866-4868.
141. Masya LM, Young JM, Solomon MJ et al. Preferences for outcomes of treatment for rectal cancer: patient and clinician utilities and their application in an interactive computer-based decision aid. Dis Colon Rectum 2009; 52: 1994-2002.
142. Solomon MJ, Pager CK, Keshava A et al. What do patients want? Patient preferences and surrogate decision making in the treatment of colorectal cancer. Dis Colon Rectum 2003; 46: 1351-1357.
143. Papillon J, Mayer M, Montbarbon JF et al. A new approach to the management of epidermoid carcinoma of the anal canal. Cancer 1983; 51: 1830-1837.
144. Vuong T, Belliveau PJ, Michel RP et al. Conformal preoperative endorectal brachytherapy treatment for locally advanced rectal cancer: early results of a phase I/II study. Dis Colon Rectum 2002; 45: 1486-1493; discussion 1493-1495.
145. Vuong T, Devic S, Moftah B et al. High-dose-rate endorectal brachytherapy in the treatment of locally advanced rectal carcinoma: technical aspects. Brachytherapy 2005; 4: 230-235.
146. Ortholan C, Romestaing P, Chapet O, Gerard JP. Correlation in rectal cancer between clinical tumor response after neoadjuvant radiotherapy and sphincter or organ preservation: 10-year results of the Lyon R 96-02 randomized trial. Int J Radiat Oncol Biol Phys 2012; 83: e165-e171.